直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
  • Articles & Books
    • Ad Law Buzz Blog
    • At the PTAB Blog
    • European IP Blog
    • Federal Circuit IP Blog
    • INCONTESTABLE® Blog
    • Prosecution First Blog
  • Events & Webinars
  • IP Updates
  • Podcasts
    • AI + Finnegan
    • AI + Copyright
    • AI + Patent
    • AI + Privacy
    • AI + Trade Secrets
    • AI + Trademark
  • Unified Patent Court (UPC) Hub

At the PTAB Blog

Claim Construction Leads to Unpatentability for Lack of Written Description Support

September 20, 2023

Authored and Edited by Amanda K. Murphy, Ph.D.; Shannon M. Patrick; Stacy Lewis†

Holding

In Tokyo Ohka Koygo., Ltd. v. Fujifilm Electronic Materials U.S.A., Inc., PGR2022-00010, Paper 28 (P.T.A.B. May 31, 2023), the Patent Trial and Appeal Board (“the Board”) held all challenged claims unpatentable for obviousness.

Background

Petitioner Tokyo Ohka Koygo (“TOK”) challenged claims 1-5 of Fujifilm’s U.S. Patent No. 10,927,329 (“the ’329 patent”) as unpatentable for obviousness under 35 U.S.C. §103 and lack of written description under §112(a). Independent claim 1 read:

    1. A cleaning composition, comprising:
      1. hydroxylamine;
      2. an alkanolamine in an amount of at most about 3% by weight of the composition; 
      3. an alkylene glycol; and
      4. water

wherein the pH of the composition is from about 7 to about 11.

The parties disputed the proper construction of the claim term “cleaning composition.” The parties agreed that the term refers to “a composition for removing residues from substrates.” Id. at *6. However, Patent Owner Fujifilm argued that “cleaning composition” should be construed to additionally include “at least a redox agent, a chelating agent, a metal corrosion inhibitor, an organic solvent, and water.” Id. at *7.

Board Decision

The Board noted that the claim language does not specify a purpose for the cleaning composition, but the specification “consistently states that the disclosed cleaning composition is for removing residues formed on semiconductor substrates.” Id. at *7. According to the Board, Patent Owner Fujifilm’s proposed construction would improperly rewrite the claim. Because the intrinsic evidence was “unambiguous,” the proper construction is limited to the four components expressly recited in the claim. Id. at *11. The Board explained:

Although the ’329 patent describes a cleaning composition that comprises a redox agent, a chelating agent, a metal corrosion inhibitor, an organic solvent, and water, we see no reason to construe the term “cleaning composition” itself to require these components. Claim 1 expressly recites the components that comprise the claimed “cleaning composition,” without expressly including or precluding a chelating agent or a metal corrosion inhibitor. … The ’329 patent specification does teach a cleaning composition that includes a redox agent, a chelating agent, a metal corrosion inhibitor, an organic solvent, and water, but claim 1 is directed to a cleaning composition that expressly requires only a subset of those components.

Id. at *8-9.

Under this construction, the Board agreed with Petitioner TOK that the challenged claims lacked written description support. “The ’329 patent does not reasonably convey to a POSA that the inventor was in possession of cleaning compositions that do not include a chelating agent or a metal corrosion inhibitor.” Id. at *13 (emphasis added).

[T]he ’329 patent specification explicitly teaches that a redox agent, a chelating agent, a metal corrosion inhibitor, an organic solvent, and water are mandatory components of the cleaning composition described therein. . . . Claim 1, however, does not require that the cleaning composition include a chelating agent or a metal corrosion inhibitor. . . . Therefore, establishing proper written description support for claim 1 requires more than showing that the inventor was in possession of a cleaning composition that includes a redox agent, a chelating agent, a metal corrosion inhibitor, an organic solvent, and water; the ’329 patent must also show that the inventor was in possession of a cleaning composition that includes only a redox agent (hydroxylamine), an organic solvent (an alkylene glycol), water, and an alkanolamine.   

Id.

The Board did not reach the obviousness grounds.

Take-aways

For the prosecutor, this case is a reminder to avoid wherever possible disclosing but not claiming subject matter. Disclosed but unclaimed subject matter is dedicated to the public, and, as seen in this case, may potentially lead to written description support issues.

For the PTAB practitioner, this case illustrates why a party may want to consider including alternative positions in its briefing. Here, the Board noted that Patent Owner Fujifilm “does not address whether the challenged claims are sufficiently supported by the ’329 patent using any other construction of ‘cleaning composition.’” As a result, the Board concluded that Fujifilm’s written description position was unrebutted.

Tags

claim construction

Related Practices

Patent Office Invalidation Proceedings

Related Industries

AI, Electronics, and Information Technology

Electronic Devices and Components

Consumer Goods and Services

Consumer Products

Related Offices

Atlanta, GA

London

Contacts

Amanda K. Murphy, Ph.D.
Partner
London
+44 (0)20 7864 2814
Email
Shannon M. Patrick
Associate
Atlanta, GA
+1 404 653 6558
Email

†Stacy Lewis is a Law Clerk at Finnegan

Copyright © 2023 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP. 



DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.

Related Insights

Conference

IP Life Sciences Forum 2026

December 13-15, 2026

Coral Gables

Seminar

Global Patent Strategies for Life Sciences and Chemical Innovations: Key Developments in Europe and the United States – Osaka

December 10, 2026

Osaka

Seminar

Global Patent Strategies for Life Sciences and Chemical Innovations: Key Developments in Europe and the United States – Tokyo

December 8, 2026

Tokyo

Workshop

Winning Global IP Disputes: Litigation, SEP, and FRAND Strategies

November 20, 2026

Shanghai

Reception

2026 National Veterans Legal Services Program Annual Benefit Reception

November 19, 2026

Washington, DC

Webinar

Data and Market Exclusivity: An Update on China’s New Law and Comparisons to the US and Europe

November 19, 2026

Webinar

Workshop

From Innovation to Commercialization: U.S. Patent Strategies, Licensing, and IP Transaction Best Practices

November 17, 2026

Beijing

Charitable

2026 ALYN Hospital Wheels of Love Ride

November 8-12, 2026

Northern District

Seminar

U.S. Patent Litigation 2026: Key Developments, Strategic Trends, and Winning Before Trial

November 6, 2026

Taipei

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP